Greiner J W, Tobi M, Fisher P B, Langer J A, Pestka S
Int J Cancer. 1985 Aug 15;36(2):159-66. doi: 10.1002/ijc.2910360206.
We have previously shown that a recombinant human leukocyte interferon (IFN-alpha A)5 can mediate an increase in cell surface tumor antigen expression in human carcinoma cells but not normal cells (Greiner et al., 1984). Such a biological response modifier may prove useful in circumventing the problem of antigenic heterogeneity and could increase the effectiveness of monoclonal antibodies (MAbs) for detection and/or therapy of human carcinoma lesions. These studies also revealed that, within populations of human carcinoma cells, there exist subpopulations which are unresponsive to the antigen-enhancing properties of IFN-alpha A. Utilizing cloned cell populations from the MCF-7 human breast carcinoma cell line, we now report the differential responsiveness to the tumor antigen enhancing and antiproliferative actions of IFN-alpha A. Binding of MAb B72.3 to the 220-400 kd tumor antigen, TAG-72, is increased by IFN-alpha A treatment on the surface of the parental MCF-7 cell line and 2 cloned cell populations. A third MCF-7 clone does not express this antigen either before or after IFN-alpha A treatment, but does express a 90 kd tumor antigen and carcinoembryonic antigen which bind MAbs B6.2 and B1.1, respectively. The level of expression of these 2 surface tumor antigens remained unchanged upon interferon treatment. The growth of the parental MCF-7 cells and the 3 cloned cell lines was, however, inhibited by IFN-alpha A. These cell lines also exhibited approximately the same number of interferon receptors with similar binding affinities for IFN-alpha A. The results demonstrate a dissociation of two biological actions of IFN-alpha A-antiproliferative activity and enhancement of tumor antigen expression within a cloned human carcinoma cell line. Our studies also indicate that the differential response of cloned MCF-7 cells to tumor antigen modulation by interferon involves alterations in the transduction of signals occurring distal to receptor occupancy within the biochemical pathways responsible for the actions of this biological response modifier. In addition, the clonal cell lines we have isolated which differ in their responsiveness to interferon should prove valuable in analyzing the molecular basis of interferon actions and may provide insights into the mechanism by which this compound confers its antitumor activity.
我们之前已经表明,重组人白细胞干扰素(IFN-αA)5可介导人癌细胞而非正常细胞表面肿瘤抗原表达的增加(Greiner等人,1984年)。这种生物反应调节剂可能在规避抗原异质性问题方面有用,并且可以提高单克隆抗体(MAb)用于检测和/或治疗人癌病变的有效性。这些研究还表明,在人癌细胞群体中,存在对IFN-αA的抗原增强特性无反应的亚群体。利用来自MCF-7人乳腺癌细胞系的克隆细胞群体,我们现在报告对IFN-αA的肿瘤抗原增强和抗增殖作用的差异反应性。在亲本MCF-7细胞系和2个克隆细胞群体的表面,IFN-αA处理可增加MAb B72.3与220 - 400 kd肿瘤抗原TAG-72的结合。第三个MCF-7克隆在IFN-αA处理之前或之后均不表达该抗原,但表达分别与MAb B6.2和B1.1结合的90 kd肿瘤抗原和癌胚抗原。干扰素处理后,这2种表面肿瘤抗原的表达水平保持不变。然而,亲本MCF-7细胞和3个克隆细胞系的生长受到IFN-αA的抑制。这些细胞系还表现出大致相同数量的干扰素受体,对IFN-αA具有相似的结合亲和力。结果表明,在克隆的人癌细胞系中,IFN-αA的两种生物学作用——抗增殖活性和肿瘤抗原表达增强——相互分离。我们的研究还表明,克隆的MCF-7细胞对干扰素介导的肿瘤抗原调节的差异反应涉及在负责这种生物反应调节剂作用的生化途径中,受体占据后发生的信号转导改变。此外,我们分离出的对干扰素反应性不同的克隆细胞系,在分析干扰素作用的分子基础方面应具有重要价值,并可能为该化合物赋予其抗肿瘤活性的机制提供见解。